ライフサイエンスコーパス: National Cancer Institute

1 Criteria for Adverse Events, grades 3 to 5 (National Cancer Institute).

2 more than two hundred types according to the National Cancer Institute.

3 ational Heart, Lung, and Blood Institute and National Cancer Institute.

4 for Healthcare Research and Quality, and the National Cancer Institute.

5 National Institutes of Health National Cancer Institute.

6 ernational Breast Cancer Study Group, and US National Cancer Institute.

7 UK, the UK Department of Health, and the US National Cancer Institute.

8 National Institutes of Health/National Cancer Institute.

9 nnings in 1937 with the establishment of the National Cancer Institute.

10 MD Anderson Cancer Center, National Cancer Institute.

11 US National Institutes of Health/National Cancer Institute.

12 abetes and Digestive and Kidney Diseases and National Cancer Institute.

13 Cancer Agency (BCCA), sponsored by the U.S. National Cancer Institute.

14 US National Institutes of Health, National Cancer Institute.

15 ention and Research Institution of Texas and National Cancer Institute.

16 s for Disease Control and Prevention and the National Cancer Institute.

17 orence Koplow Charitable Foundation, and the National Cancer Institute.

18 PRIMARY FUNDING SOURCE: National Cancer Institute.

19 the synthesized compounds was tested by the National Cancer Institute.

20 National Institute on Aging and National Cancer Institute.

21 designated as a vulnerable population by the National Cancer Institute.

22 nal Heart, Lung, and Blood Institute and the National Cancer Institute.

23 ood frequency questionnaire developed by the National Cancer Institute.

24 and Development Center of Excellence and the National Cancer Institute.

25 Department of Veterans Affairs and National Cancer Institute.

26 University of Washington and National Cancer Institute.

27 Primary Funding Source: The National Cancer Institute.

28 coordinating center funded by the NHGRI and National Cancer Institute.

29 logy, and End Results (SEER) database of the National Cancer Institute.

30 ency for Healthcare Research and Quality and National Cancer Institute.

31 Studies of phenanthriplatin in the National Cancer Institute 60-cell tumor panel screen rev

32 008, a WT-GIST clinic was established at the National Cancer Institute, allowing the development of a

33 National Cancer Institute, American Cancer Society, Agen

34 US National Cancer Institute, American Lebanese Syrian Asso

35 National Cancer Institute, American Lebanese Syrian Asso

36 National Cancer Institute, American Lebanese Syrian Asso

37 National Institute of Mental Health, National Cancer Institute, American Lebanese Syrian Asso

38 National Cancer Institute, American Lebanese-Syrian Asso

39 National Cancer Institute, American Lebanese-Syrian Asso

40 ancer epidemiology research supported by the National Cancer Institute and a selected sample of the c

41 National Cancer Institute and Adaptive Biotechnologies.

42 US National Cancer Institute and AstraZeneca Pharmaceutical

43 National Cancer Institute and Centers for Disease Contro

44 National Cancer Institute and Centers for Disease Contro

45 NIAID, National Cancer Institute and Clinical Center Intramural

46 of Allergy and Infectious Diseases (NIAID), National Cancer Institute and Clinical Center Intramural

47 Paul Pinsky of the US National Cancer Institute and colleagues describe the im

48 National Cancer Institute and CycleforSurvival Fund, Mem

49 PRIMARY FUNDING SOURCE: National Cancer Institute and Department of Veterans Aff

50 US National Cancer Institute and ECOG-ACRIN Cancer Research

51 National Cancer Institute and Enzon Pharmaceuticals.

52 Patients were classified according to National Cancer Institute and FDA criteria, and the rate

53 US National Cancer Institute and Massachusetts General Hosp

54 National Cancer Institute and National Comprehensive Can

55 zed cancer epidemiology grants funded by the National Cancer Institute and published literature for 2

56 by Developmental Therapeutic Program at the National Cancer Institute and represented promising cand

57 National Cancer Institute and Sanofi-Aventis.

58 The National Cancer Institute and the US Food and Drug Admin

59 a computer encrypted numbering system at the National Cancer Institute) and became open-label when ea

60 from the AIDS and Cancer Specimen Resource (National Cancer Institute) and Johns Hopkins Hospital in

61 nstitute of Allergy and Infectious Diseases, National Cancer Institute, and Clinical Center Intramura

62 ous Diseases, National Institutes of Health, National Cancer Institute, and Gilead Sciences.

63 Jabbs Foundation (Birmingham, UK), US National Cancer Institute, and Henry J Predolin Foundati

64 Physicians, payers, the National Cancer Institute, and other stakeholders need t

65 lege of Surgeons Commission on Cancer or the National Cancer Institute, and quality measure reporting

66 Here we used the National Cancer Institute Antitumor Cell Line Panel (the

67 The trial has been registered at the US National Cancer Institute as #EU-20554, NCT00281983.

68 US National Cancer Institute, AstraZeneca Pharmaceuticals.

69 US National Cancer Institute at the National Institutes of

70 US National Cancer Institute (award number UC2CA148310).

71 osis was 5 years; 68% were boys; and 43% had National Cancer Institute-based high-risk disease.

72 National Cancer Institute, Bayer Oy (formerly Schering O

73 absolute risk of BC >/= 1.66% (based on the National Cancer Institute BC Risk Assessment Tool or an

74 Recently, the National Cancer Institute began exploring opportunities

75 xcellent yields (94-99%) and screened by the National Cancer Institute (Bethesda, MD) on about 60 hum

76 re reviewed in patients with melanoma at the National Cancer Institute between January 1, 1953, and D

77 ogistic regression models with data from the National Cancer Institute Breast and Prostate Cancer Coh

78 , costs, and health state utilities from the National Cancer Institute Breast Cancer Surveillance Con

79 Exelixis, National Institutes of Health and National Cancer Institute Cancer Center Support Grant P3

80 s with advanced cancer were recruited from a National Cancer Institute cancer center, a Veterans Admi

81 2013, 207 patients with advanced cancer at a National Cancer Institute cancer center, a Veterans Affa

82 nstitutional breast MR examinations from the National Cancer Institute Cancer Imaging Archive, along

83 National Cancer Institute (Cancer Therapy Evaluation Pro

84 nadian Cancer Society Research Institute, US National Cancer Institute, Cancer Council Australia, Roy

85 s corresponding to 69 proteins across all 60 National Cancer Institute cell lines in biological tripl

86 ntive Oncology, in collaboration with the US National Cancer Institute Center for Global Health, held

87 h review by working group leadership and the National Cancer Institute Clinical Trials Planning Meeti

88 ered with the National Institutes of Health, National Cancer Institute, Clinical Trials (PDQ), number

89 a from six prospective cohort studies in the National Cancer Institute Cohort Consortium, comprising

90 points were acute toxicity according to the National Cancer Institute Common Terminology Criteria fo

91 Toxic effects are reported using National Cancer Institute Common Terminology Criteria fo

92 the time to grade 2 neuropathy by using the National Cancer Institute Common Terminology Criteria fo

93 ling), and grade 5 (death) as defined by the National Cancer Institute Common Terminology Criteria fo

94 reatment-related adverse events according to National Cancer Institute Common Terminology Criteria fo

95 Adverse events were graded according to the National Cancer Institute Common Terminology Criteria fo

96 The main treatment-related National Cancer Institute Common Terminology Criteria gr

97 Toxicities were scored by using National Cancer Institute Common Toxicity Criteria 2.0 a

98 tively collected by investigators (graded by National Cancer Institute Common Toxicity Criteria [vers

99 and elevations in serum creatinine based on National Cancer Institute Common Toxicity Criteria for A

100 ported acute and 6-month toxic effects using National Cancer Institute Common Toxicity Criteria, and

101 Toxicity was evaluated using National Cancer Institute Common Toxicity Criteria, vers

102 e toxicity rate was defined according to the National Cancer Institute Common Toxicity Criteria.

103 tinib-treated patients, the overall risk for National Cancer Institute-Common Terminology Criteria fo

104 basis of cell biologic data together with a National Cancer Institute COMPARE study.

105 disease (7 of 8 cancers), or were treated at National Cancer Institute Comprehensive Cancer Centers o

106 mprove early-detection biopsy decisions, the National Cancer Institute conducted a prospective valida

107 Recently, the National Cancer Institute convened a Strategic Workshop

108 n of Cancer Control and Population Sciences, National Cancer Institute, convened a workshop to discus

109 DLBCL (stages II-IV) in the NCCTG (Alliance) National Cancer Institute Cooperative Group (USA).

110 uropathy was assessed at clinic visits using National Cancer Institute criteria and prospectively gra

111 risk groups on the basis of a combination of National Cancer Institute criteria, cytogenetics, and ea

112 standard- or high-risk disease according to National Cancer Institute criteria.

113 ritis and Musculoskeletal and Skin Diseases, National Cancer Institute, Damon Runyon Cancer Research

114 nal Heart, Lung, and Blood Institute and the National Cancer Institute, Danish Cancer Society, Novo N

115 eral nonhydroxamate compounds, obtained from National Cancer Institute database, which potentially in

116 against US Food and Drug Administration and National Cancer Institute databases of approved indicati

117 We explored the National Cancer Institute databases, which include data

118 In this issue of Blood, Nicolae et al at the National Cancer Institute describe a series of Epstein-B

119 e interval [CI], 0.57-0.77), being seen at a National Cancer Institute-designated cancer center (HR,

120 esenting for surgical evaluation at a single National Cancer Institute-designated cancer center withi

121 ategorized into 3 mutually exclusive groups: National Cancer Institute-Designated Cancer Centers (NCI

122 cytoreductive surgery and chemotherapy at 6 National Cancer Institute-designated cancer centers betw

123 to IV ovarian cancer who were treated at six National Cancer Institute-designated cancer centers.

124 prequalify imaging facilities at all of the National Cancer Institute-designated comprehensive and c

125 , medical oncologists affiliated with the 40 National Cancer Institute-designated comprehensive cance

126 Physicians at a tertiary-care National Cancer Institute-designated comprehensive cance

127 ed institutional database was conducted at a National Cancer Institute-designated comprehensive cance

128 gastric cancer surgery database at a single National Cancer Institute-designated comprehensive cance

129 The sample included 39 National Cancer Institute-designated Comprehensive Cance

130 and outpatient surgical oncology unit of one National Cancer Institute-designated comprehensive cance

131 cal outcomes were collected and studied at a National Cancer Institute-designated comprehensive cance

132 ncluded patients who were being treated at a National Cancer Institute-designated comprehensive cance

133 etween July 3, 2014, and June 30, 2015, at a National Cancer Institute-designated comprehensive cance

134 erspective into adverse event reporting, the National Cancer Institute developed a patient-reported o

135 The National Cancer Institute developed the Centers for Quan

136 s the 60-cell line panel (the NCI-60) of the National Cancer Institute Developmental Therapeutics Pro

137 d dual-fluorescent proteolytic screen of the National Cancer Institute diversity library to identify

138 ased on available structures with use of the National Cancer Institute diversity set and a panel of D

139 A small molecule from the National Cancer Institute Diversity Set designated NSC 1

140 Through virtual screening of the National Cancer Institute Diversity Set II and in vitro

141 nternational, as well as with staff from the National Cancer Institute Enterprise Vocabulary Services

142 onal Health and Medical Research Council, US National Cancer Institute, European Organisation for Res

143 UK Medical Research Council, National Cancer Institute, European Science Foundation,

144 National Institutes of Health, National Cancer Institute, FDA Center for Tobacco Produc

145 of added sugars were identified by using the National Cancer Institute food categories.

146 and End Results (SEER) 18 registry from the National Cancer Institute for all PMCTs diagnosed from 1

147 ters for Medicare and Medicaid Services, the National Cancer Institute, foreign government agencies i

148 Department for International Development UK, National Cancer Institute, Frederick National Laboratory

149 t imaging registries that participate in the National Cancer Institute-funded Breast Cancer Surveilla

150 Our analysis of GEO databases (National Cancer Institute) further revealed a statistica

151 The National Cancer Institute Genomic Data Commons (GDC) is

152 The NET Task Force of the National Cancer Institute GI Steering Committee convened

153 Pfizer and National Cancer Institute grant to the Children's Oncolo

154 The National Cancer Institute has played an increasingly imp

155 Compound 2i was then tested by the National Cancer Institute Human Tumor Cell Line Anti-Can

156 .5 times greater than dollars awarded by the National Cancer Institute in 2000.

157 ute of Environmental Health Sciences and the National Cancer Institute in conjunction with the annual

158 , PATH, the Peruvian Ministry of Health, the National Cancer Institute in Lima, and the Regional Canc

159 nal Agency for Research on Cancer and the US National Cancer Institute in September, 2013.

160 y concurrently from 2007 through 2014 at the National Cancer Institute in the United States.

161 Novartis, United States National Cancer Institute, International Breast Cancer S

162 The PAM Task Force of the National Cancer Institute Investigational Drug Steering

163 The US National Cancer Institute is already implementing some o

164 dicine Centre, East Midlands Innovation, the National Cancer Institute, Joseph Mitchell Trust, Royal

165 ey Cancer; US National Institutes of Health, National Cancer Institute Kidney Cancer Specialized Prog

166 earch Council, Cancer Australia, Sarcoma UK, National Cancer Institute, Liddy Shriver Sarcoma Initiat

167 ute of Texas, Leukemia and Lymphoma Society, National Cancer Institute, MD Anderson Cancer Center.

168 ed DNA and RNA unwinding in the 827-compound National Cancer Institute Mechanistic Set.

169 US National Cancer Institute, Merck Sharp & Dohme.

170 usual dietary intakes of folate by using the National Cancer Institute method to adjust two 24-h diet

171 The National Cancer Institute method was used to estimate th

172 beverages were obtained with the use of the National Cancer Institute method.

173 by Hispanic and Latino backgrounds by using National Cancer Institute methodology.

174 ls (TCA-cHL) were identified in two cohorts (National Cancer Institute, n = 38; Basel, n = 12).

175 ion of Cancer Treatment and Diagnosis at the National Cancer Institute (National Institutes of Health

176 nstitute of Allergy and Infectious Diseases, National Cancer Institute (National Institutes of Health

177 National Cancer Institute, National Heart Lung and Blood

178 US National Cancer Institute, National Institutes of Health

179 abetes and Digestive and Kidney Diseases and National Cancer Institute, National Institutes of Health

180 National Cancer Institute, National Institutes of Health

181 from June 1, 2012, to July 30, 2016, at the National Cancer Institute, National Institutes of Health

182 ational Heart, Lung, and Blood Institute and National Cancer Institute, National Institutes of Health

183 National Cancer Institute, National Institutes of Health

184 nitiative, and Cancer Center Support (Core), National Cancer Institute, National Institutes of Health

185 National Cancer Institute, National Palliative Care Rese

186 on on Cancer (CoC) -accredited hospitals and National Cancer Institute (NCI) -designated cancer cente

187 Through a collaborative effort between the National Cancer Institute (NCI) and the Dialogue on Reve

188 training at cancer centers designated by the National Cancer Institute (NCI) and the National Compreh

189 Assessment Teams (IRATs) were funded by the National Cancer Institute (NCI) as supplemental grants t

190 e postoperative events were graded using the National Cancer Institute (NCI) Common Terminology Crite

191 risk groups on the basis of a combination of National Cancer Institute (NCI) criteria, cytogenetics,

192 t was identified by virtual screening of the National Cancer Institute (NCI) diverse small-molecule d

193 More than half a century ago, the National Cancer Institute (NCI) established a network of

194 National Cancer Institute (NCI) grants 3P50CA126752 and

195 Finally, for many years agencies such as the National Cancer Institute (NCI) have encouraged the deve

196 The National Cancer Institute (NCI) Mouse Models of Human Ca

197 A National Cancer Institute (NCI) sponsored, multicenter,

198 or T-cell immunophenotype; and in those with National Cancer Institute (NCI) standard- or high-risk c

199 We used the National Cancer Institute (NCI) Surveillance, Epidemiolo

200 The COG-National Cancer Institute (NCI) TARGET AML initiative as

201 Resources (GSR) is a website provided by the National Cancer Institute (NCI) that aims to help resear

202 Compounds obtained from the National Cancer Institute (NCI) were docked to the recep

203 pril 17, 2010, scientists from academia, the National Cancer Institute (NCI), and the Food and Drug A

204 ated according to protocols available at the National Cancer Institute (NCI), Bethesda, MD.

205 The US National Cancer Institute (NCI), in collaboration with s

206 On June 27-28, 2011, scientists from the National Cancer Institute (NCI), NASA, and academia met

207 n = 0.2 mum) in almost all cell lines of the National Cancer Institute (NCI)-60 cell line screen and

208 differences in guideline concordance between National Cancer Institute (NCI)-designated and other cen

209 insurance, and those who received care at a National Cancer Institute (NCI)-designated cancer center

210 n areas that do and do not contain one of 69 National Cancer Institute (NCI)-Designated Cancer Center

211 ence interval (CI) 1.05-1.16), and care at a National Cancer Institute (NCI)-designated center (OR 1.

212 iology and End Results (SEER) program of the National Cancer Institute (NCI).

213 cases in a stage-1 case-only analysis of the National Cancer Institute (NCI, 541 cases with FH and 13

214 Responses were determined by using the 1996 National Cancer Institute (NCI-96) and 2008 Internationa

215 ancer Society; Swedish Research Council; and National Cancer Institute (NIH).

216 Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH.

217 sing the Developmental Therapeutics Program (National Cancer Institute/NIH), virtual ligand screening

218 Intramural Research Program of the US National Cancer Institute/NIH/DHHS, and the American Can

219 (25 mg per day) compared with placebo in the National Cancer Institute of Canada (NCIC) Clinical Tria

220 trial of the Gynecologic Oncology Group and National Cancer Institute of Canada Clinical Trials Grou

221 ients in two independent phase 3 trials (the National Cancer Institute of Canada Clinical Trials Grou

222 Retrospective analyses of the National Cancer Institute of Canada Clinical Trials Grou

223 city as compared with 37% of patients in the National Cancer Institute of Canada SR2 (CAN-NCIC-SR2: P

224 ng the present analysis, was provided by the National Cancer Institute of National Institutes of Heal

225 US National Cancer Institute of the National Institutes of

226 National Cancer Institute of the National Institutes of

227 ECOG-ACRIN Cancer Research Group, National Cancer Institute of the National Institutes of

228 rly Career Cancer Systems Biologists and the National Cancer Institute of the NIH, focused on the int

229 National Cancer Institute of the US National Institutes

230 National Cancer Institute of the US National Institutes

231 A workshop at the National Cancer Institute on May 2, 2016, considered the

232 we summarize cohort studies conducted by the National Cancer Institute on meat and dairy intake in re

233 ogressive urothelial carcinoma enrolled in a National Cancer Institute open-label, nonrandomized, pha

234 All patients were treated at either the National Cancer Institute or the Department of Breast Me

235 Using the National Cancer Institute Patterns of Care Studies and l

236 Using the National Cancer Institute Patterns of Care Study, we use

237 iser Permanente Northern California and U.S. National Cancer Institute Persistence and Progression St

238 f a randomized controlled trial (RCT) by the National Cancer Institute Physicians Data Query and addi

239 National Cancer Institute, private foundations, and inst

240 of prostate cancer aggressiveness, the first National Cancer Institute Prostate Cancer Genetics Works

241 US National Cancer Institute (R01CA143971).

242 The National Cancer Institute recently launched its Communit

243 The National Cancer Institute recognizes centers of excellen

244 orms for 155 actively accruing trials in the National Cancer Institute's (NCI's) Clinical Trials Coop

245 EORTC QLQ-C30 and EORTC QLQ-CR38, and National Cancer Institute's (NCI) PRO-CTCAE were selecte

246 Top1-mediated DNA cleavage assay and in the National Cancer Institute's 60 cell line cytotoxicity as

247 ide (CL) to permit an evaluation against the National Cancer Institute's 60-cell line panel and allow

248 Using the National Cancer Institute's anticancer drug screen data,

249 cancer cases and 12,760 controls within the National Cancer Institute's Breast and Prostate Cancer C

250 used a nested case-control design within the National Cancer Institute's Breast and Prostate Cancer C

251 Data from the National Cancer Institute's Breast and Prostate Cancer C

252 ance metrics and criteria established by the National Cancer Institute's Clinical Proteomic Tumor Ana

253 ymptomatic AEs using a PRO adaptation of the National Cancer Institute's Common Terminology Criteria

254 severity of adverse events assessed with the National Cancer Institute's Common Terminology Criteria

255 Complications were evaluated with the National Cancer Institute's Common Terminology Criteria

256 lizing clinical trials conducted through the National Cancer Institute's Cooperative Group Program.

257 ed in EBOV entry, gene array findings in the National Cancer Institute's NCI-60 panel of human tumor

258 9, 2003, and 2007 were examined by using the National Cancer Institute's Patterns of Care Studies.

259 update of clinical research supported by the National Cancer Institute's Phase I/II prostate cancer c

260 urce use, including information found in the National Cancer Institute's Physician Data Query and UpT

261 cs systems, which has been recognized by the National Cancer Institute's program for CER and personal

262 2012 (N = 5,284) were recruited through the National Cancer Institute's SEER Program.

263 Data were obtained from the National Cancer Institute's SEER registry for all patien

264 1, 2004, through December 31, 2005, from the National Cancer Institute's Surveillance, Epidemiology,

265 trospective cohort study using data from the National Cancer Institute's Surveillance, Epidemiology,

266 The National Cancer Institute's Surveillance, Epidemiology,

267 der (40-84 years) non-Hispanic whites in the National Cancer Institute's Surveillance, Epidemiology,

268 ormed using an independent data set from the National Cancer Institute's Surveillance, Epidemiology,

269 The National Cancer Institute's Surveillance, Epidemiology,

270 ut one in six of all cancers reported to the National Cancer Institute's Surveillance, Epidemiology,

271 12 from the 18 US regional registries of the National Cancer Institute's Surveillance, Epidemiology,

272 National Cancer Institute, Sanofi-Aventis, and Abbott La

273 the Connecticut Tumor Registry, the original National Cancer Institute SEER site, to determine trends

274 The National Cancer Institute sponsored a clinical trials pl

275 independent registries and disease-specific, National Cancer Institute-sponsored clinics.

276 dels for HIV-related eligibility criteria in National Cancer Institute-sponsored studies are instruct

277 iew of HIV-related eligibility criteria from National Cancer Institute-sponsored studies.

278 US National Cancer Institute, St Baldrick's Foundation, and

279 A National Cancer Institute summit, held in 2007, on neuro

280 NIDCR support decreased in most years, while National Cancer Institute support increased and approach

281 The model was calibrated to National Cancer Institute Surveillance, Epidemiology, an

282 in 1 of 9 population-based registries of the National Cancer Institute Surveillance, Epidemiology, an

283 Evidence from the US National Cancer Institute Surveillance, Epidemiology, an

284 nal SNPs, population incidence rate from the National Cancer Institute-Surveillance, Epidemiology, an

285 tion-based case-control study of NHL in four National Cancer Institute-Surveillance, Epidemiology, an

286 , Epidemiology, and End Results registry and National Cancer Institute survey.

287 held on May 4, 2016 with officials from the National Cancer Institute, the FDA, members of the Ameri

288 The National Cancer Institute, the National Heart, Lung, and

289 e in November 2012 in collaboration with the National Cancer Institute, the National Institute on Agi

290 enter quasi-experimental study funded by the National Cancer Institute to evaluate patient navigation

291 is one of three pilot projects funded by the National Cancer Institute to explore new approaches to c

292 National Cancer Institute, U.S. Department of Defense, P

293 US National Cancer Institute, US Department of Defense, San

294 US National Cancer Institute, US National Institutes of Hea

295 National Cancer Institute, Walther Cancer Institute, Ind

296 oncurrently with a workshop sponsored by the National Cancer Institute, we identified key "drivers" f

297 The National Cancer Institute, which currently supports an a

298 I-60 cell line database compiled by the U.S. National Cancer Institute, which has been extensively ch

299 National Cancer Institute with contributions from the Na

300 ssessed for response and progression by 1996 National Cancer Institute-Working Group (NCI-WG) criteri